AffyImmune Therapeutics to Present Initial Clinical Results at Upcoming CAR-TCR Summit

August 19, 2021

NATICK, Mass. (AUGUST 19, 2021) – AffyImmune Therapeutics, Inc., a clinical stage biotechnology company finding safe, effective ways to use CAR T cells against solid cancers, announced today that scientific co-founder Moonsoo Jin will present twice at Hanson Wade’s 6th CAR-TCR Summit being held virtually August 30 – September 2.

Dr. Jin’s first presentation “Developing Manufacturing and Quality Control Platforms for Cell Immunotherapy” will occur as part of the CAR-TCR 101 Deep Dive Day Bootcamp at 1:30 pm EST on August 30. In this talk, he will explore strategies to optimize CMC for high quality cell production, summarize key quality control parameters and assays, and discuss how to build product development teams to effectively manage change controls and scale.

His second presentation “First in Patient Clinical Readouts for Affinity Tuned CAR T with Real-Time Monitoring of Response” is part of the Clinical Management track on September 1 at 2:30 pm EST. There, Dr. Jin will expand on AffyImmune’s Tune & Track platform, including early insights into clinical experiences and results.

“We are honored to have two speaking slots at this year’s CAR-TCR conference,” began Eric von Hofe, President of AffyImmune. “With these presentations, AffyImmune will demonstrate its technological and clinical advancements from the past year, particularly with our Tune & Track platform.”

Interested parties can register at

Contact Information:
Eric von Hofe
AffyImmune Therapeutics, Inc.